In this phase 3b/4 study, people with advanced kidney cancer were treated with a less frequent but continuous dose of the combination of ipilimumab plus nivolumab. They were treated with the combination every 8 weeks with an infusion of nivolumab on week 5 of each 8-week cycle. The tolerability and effectiveness of this treatment was assessed and compared to the standard dosing schedule (ipilimumab plus nivolumab every 3 weeks for 4 doses, followed by nivolumab every 2 or 4 weeks) to compare the benefits of the two schedules and whether patients could tolerate continuous ipilimumab plus nivolumab.
Compared with the standard ipilimumab plus nivolumab dosing schedule, the modified schedule did not improve survival or tolerability.
This study supports the continued use of the standard nivolumab/ipilimumab dosing schedule for patients with advanced kidney cancer.